Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2017 08:29 ET | Source: Neuralstem, Inc.

Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy

GERMANTOWN, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has...
July 27, 2017 08:30 ET | Source: Neuralstem, Inc.

Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants

GERMANTOWN, Md., July 27, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the pricing of...
July 26, 2017 16:50 ET | Source: Neuralstem, Inc.

Neuralstem Announces Proposed Public Offering of Common Stock and Warrants

GERMANTOWN, Md., July 26, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced it has...
July 25, 2017 08:15 ET | Source: Neuralstem, Inc.

Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder

GERMANTOWN, Md., July 25, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced top-line...
June 26, 2017 08:32 ET | Source: Neuralstem, Inc.

Neuralstem Added to the Russell Microcap® Index

GERMANTOWN, Md., June 26, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has...
May 17, 2017 16:05 ET | Source: Neuralstem, Inc.

Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder

GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...
May 10, 2017 16:05 ET | Source: Neuralstem, Inc.

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update

GERMANTOWN, Md., May 10, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, reported its financial...
April 12, 2017 07:35 ET | Source: Neuralstem, Inc.

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

GERMANTOWN, Md., April 12, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell...
March 23, 2017 07:35 ET | Source: Neuralstem, Inc.

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

Expects to Report NSI-189 Phase 2 major depressive disorder study results in Q3 ahead of scheduleGERMANTOWN, Md., March 23, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a...
March 17, 2017 07:03 ET | Source: Neuralstem, Inc.

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

GERMANTOWN, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell...

keyboard_arrow_left Previous Page